The May 28, 2019 edition of Chronicle on WCVB 5 featured our incredible Memory and Aging Program participants and a look at how we’re working together to win the battle against Alzheimer’s by finding effective treatments and prevention. See their inspiring stories and why there’s hope on the horizon in the clips below.
If you’re 40+ with normal memory or mild memory loss, you can help us in this fight. Here’s how: butler.org/ALZregistry
Chronicle’s Anthony Everett takes us inside Butler Hospital, one of the top Alzheimer’s research centers in the world.
A genetic test revealed that Dave Kalberer carried the markers for Alzheimer’s. He is now enrolled in a clinical trial through the Memory and Aging Program at Butler Hospital.
Anthony Everett reports on a billion-dollar effort underway to find breakthrough treatments in the next decade.
Alzheimer’s disease is a relentless force, stealing patients’ dignity and emotionally exhausting their families, caregivers and friends. How do we fight back?
The first infusion of an investigational drug that aims to delay or help to prevent the earliest memory loss due to Alzheimer’s disease took place in September at Butler Hospital in Providence, R.I., researchers announced.
Sam Slezak originally set out to become a trainer for professional athletes. Here’s how and why he became a project manager for a landmark national Alzheimer’s study instead.
The study seeks to identify new cognitive and neural biomarkers of preclinical Alzheimer’s disease, which would aid in earlier diagnosis and interventional treatment for the disease.
Caregiver to both her young husband and her father with dementia, now she’s supporting others in the caregiver journey.
AHEAD 3-45 is a clinical trial for a treatment aimed at preventing cognitive decline in people with preclinical Alzheimer’s Disease (AD).
MAP Director Dr. Stephen Salloway, along with other international leaders in the fight against Alzheimer’s, talk with the Providence Journal and WJAR NBC10 about how the fight to end Alzheimer’s continues despite coronavirus.
Aducanumab, an investigational drug for the treatment for Alzheimer’s disease, has been submitted to the FDA for approval with a request for Priority Review. If approved, it would become the first therapy to reduce the clinical decline of Alzheimer’s disease.
RI Chosen as 1 of 5 Sites for First Nationwide Study of Lifestyle Intervention to Reduce Risk of Cognitive Decline
The U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) is sponsored by the Alzheimer’s Association and is the first such study to be conducted in a large, diverse group of Americans across the United States.
Louisa Thompson, Ph.D., research scientist at Brown University and Butler Hospital, will evaluate how app-based and online cognitive tests might be used to detect subtle changes in memory and thinking associated with Alzheimer’s.